AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
AstraZeneca Boss Says UK ‘Isn’t the Worst Place’ to Invest
The boss of AstraZeneca Plc said he does not believe the UK is the worst place to invest, striking a conciliatory tone just ...
Investor's Business Daily on MSN14m
AstraZeneca Bounds Higher On Fourth-Quarter Beat, Upbeat Guidance
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
Stocks rise as traders await Amazon earnings and UK rate cut and US jobs data
US stocks rose on Thursday as investors digested company earnings and awaited e-commerce giant's Amazon (AMZN) results due ...
ENDPOINTS NEWS25m
As­traZeneca cuts UK fund­ing pledge; Viking says it has ‘enough’ API for tri­als
AstraZeneca cuts UK investment after government reduces site expansion support; Viking secures API supply; Jabil acquires ...
ENDPOINTS NEWS52m
As­traZeneca takes $753M charge on aban­doned com­ple­ment drug from Alex­ion deal
AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for ...